Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00127691" target="_blank" >RIV/00216224:14110/22:00127691 - isvavai.cz</a>

Result on the web

<a href="https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-of-COVID-19-vaccine-effectiveness-against-SARI-2022.pdf" target="_blank" >https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-of-COVID-19-vaccine-effectiveness-against-SARI-2022.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

Original language description

Evaluating the real-world performance of COVID-19 vaccines is critical to understanding the risks and benefits of COVID-19 vaccination programmes. ECDC has been building infrastructure to allow regular monitoring of COVID-19 vaccine effectiveness over time, using a multi-country approach that involves studies implemented in different settings across EU/EEA countries. The project allows for progressive inclusion of more countries over time and the same generic protocol is used across all countries. This update reports on a multi-country study that aims to estimate vaccine effectiveness against severe COVID-19 disease, by assessing it in individuals hospitalised for SARI. This ECDC hospital vaccine effectiveness study began at the end of 2020 and, as of 25 October 2021, has recruited 10 participating countries across the EU/EEA (Belgium, Croatia, Czechia, France, Greece, Ireland, Luxembourg, Malta, Portugal and Spain), including 42 hospitals among them (ranging from 1 to 13 hospitals per country). Five countries began their vaccination campaigns at the end of December 2020 and five in early January 2021. The analysis presented in this report aims to estimate vaccine effectiveness among SARI patients aged 50 years and older, from the first vaccination campaign start date on 27 December 2020 up to and including 30 June 2021. This end date was selected to provide a study period before wide circulation of the Delta variant of concern (VOC) in the European region.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30230 - Other clinical medicine subjects

Project

—

Continuities

—

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů